February 22, 2012 / 9:28 PM / in 6 years

US FDA panel gives nod to Vivus obesity drug

WASHINGTON, Feb 22 (Reuters) - An experimental obesity drug from Vivus Inc won a U.S. panel’s support on Wednesday, raising hopes regulators would approve a weight-loss pill for the first time in 13 years.

A panel of outside experts to the Food and Drug Administration voted 20-2 to recommend approval of Qnexa, meant to treat obesity and its accompanying health problems.

The FDA usually follows panel recommendations, although it is not required to, and a final decision is expected by April 17.

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below